Regeneron Pharmaceuticals, Inc. $REGN Stock Position Reduced by Whittier Trust Co.

Key Points

• Whittier Trust Co. reduced its stake in Regeneron Pharmaceuticals by 59.5%, holding only 340 shares worth approximately $178,000 after selling 500 shares in the second quarter.
• Analyst ratings vary for Regeneron, with Wells Fargo downgrading the stock to "equal weight" but others like Rothschild & Co giving it a "buy" rating with a target price of $890.00.
• Regeneron reported a quarterly earnings per share of $12.89, significantly surpassing analysts' expectations, alongside a revenue of $3.68 billion, marking a 3.6% year-over-year increase.

Whittier Trust Co. cut its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 59.5% during the second quarter, according to its most recent disclosure with the SEC. The institutional investor owned 340 shares of the biopharmaceutical company's stock after selling 500 shares during the period. Whittier Trust Co.'s holdings in Regeneron Pharmaceuticals were worth $178,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the stock. Klingman & Associates LLC purchased a new position in Regeneron Pharmaceuticals during the second quarter valued at approximately $201,000. Phoenix Financial Ltd. grew its position in Regeneron Pharmaceuticals by 12.3% during the second quarter. Phoenix Financial Ltd. now owns 583 shares of the biopharmaceutical company's stock valued at $306,000 after purchasing an additional 64 shares in the last quarter. Cidel Asset Management Inc. grew its position in Regeneron Pharmaceuticals by 20.4% during the second quarter. Cidel Asset Management Inc. now owns 461 shares of the biopharmaceutical company's stock valued at $242,000 after purchasing an additional 78 shares in the last quarter. International Assets Investment Management LLC grew its position in Regeneron Pharmaceuticals by 30.0% during the second quarter. International Assets Investment Management LLC now owns 724 shares of the biopharmaceutical company's stock valued at $380,000 after purchasing an additional 167 shares in the last quarter. Finally, VIRGINIA RETIREMENT SYSTEMS ET Al acquired a new stake in Regeneron Pharmaceuticals in the second quarter valued at approximately $27,853,000. 83.31% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of analysts have issued reports on the stock. Wells Fargo & Company cut shares of Regeneron Pharmaceuticals from an "overweight" rating to an "equal weight" rating and set a $580.00 target price for the company. in a research note on Friday, August 1st. Rothschild & Co Redburn assumed coverage on shares of Regeneron Pharmaceuticals in a research note on Thursday, August 14th. They issued a "buy" rating and a $890.00 target price for the company. UBS Group reiterated a "neutral" rating on shares of Regeneron Pharmaceuticals in a research note on Friday, August 1st. Jefferies Financial Group lifted their target price on shares of Regeneron Pharmaceuticals from $813.00 to $831.00 and gave the company a "buy" rating in a research note on Wednesday, August 27th. Finally, Sanford C. Bernstein lifted their target price on shares of Regeneron Pharmaceuticals from $753.00 to $781.00 and gave the company an "outperform" rating in a research note on Wednesday, August 27th. Three investment analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating, seven have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average target price of $802.35.

Regeneron Pharmaceuticals Price Performance

Shares of Regeneron Pharmaceuticals stock opened at $577.95 on Friday. The firm has a fifty day simple moving average of $576.32 and a 200-day simple moving average of $562.58. The company has a current ratio of 4.60, a quick ratio of 3.72 and a debt-to-equity ratio of 0.09. Regeneron Pharmaceuticals, Inc. has a 1-year low of $476.49 and a 1-year high of $943.83. The stock has a market capitalization of $61.26 billion, a price-to-earnings ratio of 14.57, a PEG ratio of 1.79 and a beta of 0.31.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last issued its quarterly earnings data on Friday, August 1st. The biopharmaceutical company reported $12.89 earnings per share for the quarter, topping analysts' consensus estimates of $8.43 by $4.46. Regeneron Pharmaceuticals had a net margin of 31.37% and a return on equity of 15.06%. The business had revenue of $3.68 billion during the quarter, compared to analysts' expectations of $3.30 billion. During the same period in the previous year, the company earned $11.56 earnings per share. Regeneron Pharmaceuticals's revenue for the quarter was up 3.6% on a year-over-year basis. On average, sell-side analysts expect that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Wednesday, September 3rd. Investors of record on Monday, August 18th were paid a dividend of $0.88 per share. This represents a $3.52 annualized dividend and a yield of 0.6%. The ex-dividend date was Monday, August 18th. Regeneron Pharmaceuticals's dividend payout ratio is presently 8.87%.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.

Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.